Skip to main content
. 2019 Dec 11;11(12):1992. doi: 10.3390/cancers11121992

Table 2.

Summary of tumor treatment and clinical outcome.

Case Tumor Stage (Evans) PRETEXT
Stage
Preoperative
Chemotherapy
Response
RECIST
Resection Site of Metastasis Radiotherapy Postoperative/Retrieval Chemotherapy Outcome
1 I PRETEXT 2 none No R0 Yes
Records not available
vincristine, doxorubicin, cyclophosphamide, cisplatin, ifosfamide, etoposide, irinotecan,
temozolomide
DOD
2 IV PRETEXT 3 cisplatin, doxorubicin No None Lung, Brain No irinotecan, vincristine DOD
3 IV PRETEXT 3M vincristine, cisplatin, doxorubicin Yes
CR-lung
PR- liver
R0 Lung Yes
1050cGy to whole lung 1050cGy to abdomen
carboplatin, cyclophosphamide, etoposide Alive at 8 years after diagnosis
4 IV PRETEXT 2 vincristine, irinotecan, cisplatin, doxorubicin, 5FU Yes
PR- liver
PR-lung
R0 Lung Yes
1050cGy to whole lung 1200cGy to abdomen
14.5Gy to cavity intra-op after recurrence
ifosfamide, carboplatin, vincristine, cyclophosphamide, doxorubicin
HD chemotherapy with autologous SCT
Second surgical resection
DOD
5 III PRETEXT 2 cisplatin, doxorubicin No None Lung No pazopanib DOD
6 III PRETEXT 3 vincristine, doxorubicin, cyclophosphamide Yes
PR-liver
R1
margin
Yes
Proton beam
3000cGy to abdomen
HD chemotherapy with autologous SCT Alive at 1.5 years after diagnosis

DOD: died of disease. Patient 1 had tumor rupture prior to surgery at diagnosis. In Patients 2 and 5, no resection was performed; however, patients received additional chemotherapy (listed under postoperative/retrieval chemotherapy). CR = complete response; PR = partial response.